阿那曲唑与依西美坦在辅助内分泌治疗乳腺癌中的临床疗效  

Clinical efficacy of anastrozole and exemestane in adjuvant endocrine therapy for breast cancer

作　　者：江艳 赵蓉蓉 JIANG Yan;ZHAO Rongrong(Department of Pharmacy,Shanghai Jing’an District Central Hospital,Shanghai 200040,China)

机构地区：[1]上海市静安区中心医院药剂科,上海2000400

出　　处：《癌症进展》2020年第24期2543-2546,共4页Oncology Progress

摘　　要：目的探讨阿那曲唑与依西美坦在辅助内分泌治疗乳腺癌中的临床疗效。方法根据治疗方案的不同将120例乳腺癌患者分为观察组(n=57)和对照组(n=63),观察组患者接受阿那曲唑治疗,对照组患者接受依西美坦治疗。两组患者均治疗6个月,观察并比较两组患者的临床疗效、雌激素[雌二醇(E2)、雌酮(E1)和孕酮(P)]水平、不良反应发生率及无进展生存期(PFS)。结果观察组患者的总缓解率(ORR)为52.63%,与对照组患者的52.38%比较,差异无统计学意义(P﹥0.05)。治疗4、8、12周后,两组患者的E2、E1、P水平均低于本组治疗前,差异均有统计学意义(P﹤0.05);治疗4、8、12周后,两组患者的E2、E1、P水平比较,差异均无统计学意义(P﹥0.05)。两组患者的一线PFS和二线PFS比较,差异均无统计学意义(P﹥0.05)。观察组患者面部潮红、乏力、骨关节痛、腹泻、头痛、恶心的发生率均低于对照组,差异均有统计学意义(P﹤0.05)。结论阿那曲唑与依西美坦辅助内分泌治疗乳腺癌的疗效相当,均可以降低患者体内的雌激素水平,延长患者的PFS,但在用药安全性上,阿那曲唑优于依西美坦,值得临床进一步研究。Objective To investigate the clinical efficacy of anastrozole and exemestane in adjuvant endocrine therapy for breast cancer.Method 120 patients with breast cancer were divided into the observation group(n=57,treated with anastrozole for 6 months)and the control group(n=63,treated with exemestane for 6 months).The clinical efficacy,estrogen[estradiol(E2),estrone(E1)and progesterone(P)]levels,incidence of adverse reactions and progression-free survival(PFS)were compared between the two groups.Result There was no significant difference for the overall response rate(ORR)between the observation group and the control group(52.63%vs 52.38%)(P>0.05).The levels of E2,E1 and P after 4,8 and 12 weeks of treatment in the two groups were significantly lower than those before treatment within the same group(P<0.05);there were no significant differences in E2,E1 and P levels between the two groups after 4,8 and 12 weeks of treatment(P>0.05).There were no significant differences in first-line PFS and second-line PFS between the two groups(P>0.05).The incidence of facial flushing,fatigue,bone and joint pain,diarrhea,headache and nausea in the observation group was significantly lower than that in the control group(P<0.05).Conclusion The efficacy of anastrozole and exemestane in adjuvant endocrine therapy for breast cancer is comparable,which can both reduce the level of estrogen and prolong the PFS of patients,but the safety of anastrozole is better than that of exemestane,which is worthy of further clinical study.

关 键 词：乳腺癌 内分泌治疗 阿那曲唑 依西美坦 安全性 

分 类 号：R737.9[医药卫生—肿瘤]